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Abstract
Objective—To describe and compare the clinical characteristics, outcomes, and etiology of 
pneumonia among children hospitalized with community-acquired pneumonia (CAP) with 
neurologic disorders, non-neurologic underlying conditions, and no underlying conditions.
Study design—Children <18 years old hospitalized with clinical and radiographic CAP were 
enrolled at 3 US children’s hospitals. Neurologic disorders included cerebral palsy, developmental 
delay, Down syndrome, epilepsy, non-Down syndrome chromosomal abnormalities, and spinal 
cord abnormalities. We compared the epidemiology, etiology, and clinical outcomes of CAP in 
children with neurologic disorders with those with non-neurologic underlying conditions, and 
those with no underlying conditions using bivariate, age-stratified, and multivariate logistic 
regression analyses.
Results—From January 2010–June 2012, 2358 children with radiographically confirmed CAP 
were enrolled; 280 (11.9%) had a neurologic disorder (52.1% of these individuals also had non-
neurologic underlying conditions), 934 (39.6%) had non-neurologic underlying conditions only, 
and 1144 (48.5%) had no underlying conditions. Children with neurologic disorders were older 
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and more likely to require intensive care unit (ICU) admission than children with non-neurologic 
underlying conditions and children with no underlying conditions; similar proportions were 
mechanically ventilated. In age-stratified analysis, children with neurologic disorders were less 
likely to have a pathogen detected than children with non-neurologic underlying conditions. In 
multivariate analysis, having a neurologic disorder was associated with ICU admission for 
children ≥2 years of age.
Conclusions—Children with neurologic disorders hospitalized with CAP were less likely to 
have a pathogen detected and more likely to be admitted to the ICU than children without 
neurologic disorders.
Pneumonia is a leading cause of pediatric hospitalization in the US.1–3 Although children 
with neurologic disorders—a diverse spectrum of conditions including epilepsy, 
neurodevelopmental disorders, and neuromuscular disorders—comprise a small proportion 
of the US pediatric population,4–6 this group is particularly vulnerable to severe 
complications and death from respiratory failure.7–13 Causes of respiratory failure in these 
children are multifactorial and include pulmonary scarring from recurrent aspiration, 
ineffective cough, and chest wall or spinal abnormalities prohibiting maximal chest 
expansion.9,11,14,15 Specifically, children with neurologic disorders also are at increased risk 
of complications and death from influenza virus and respiratory syncytial virus (RSV) 
infection.16–21 However, data from prospective clinical studies describing community-
acquired pneumonia (CAP) in children with neurologic disorders are limited.
We used data from the Centers for Disease Control and Prevention Etiology of Pneumonia in 
the Community (EPIC) study,3 a prospective, multicenter, population-based, active 
surveillance study, to describe and compare the clinical characteristics, outcomes, and 
pneumonia etiology among children hospitalized with CAP with neurologic disorders, non-
neurologic underlying conditions, and no underlying conditions.
Methods
From January 1, 2010 to June 30, 2012, children <18 years old were enrolled in the EPIC 
study at Le Bonheur Children’s Hospital (Memphis, Tennessee), Monroe Carell Jr 
Children’s Hospital at Vanderbilt (Nashville, Tennessee), and Primary Children’s Hospital 
(Salt Lake City, Utah).3 Informed consent was obtained before enrollment. The study 
protocol was approved by the institutional review boards at each institution and the Centers 
for Disease Control and Prevention.
Children admitted to the study hospitals with signs of acute infection, respiratory symptoms, 
and chest radiography consistent with pneumonia within 72 hours of admission were eligible 
for enrollment.3 A dedicated study radiologist at each study hospital independently reviewed 
chest radiography for final determination of radiographic pneumonia.3 Children were 
excluded if they were recently hospitalized (<7 days for immunocompetent children, <90 
days for immunosuppressed children), enrolled in the EPIC study <28 days earlier, resided 
in an extended care facility, had a clear alternative respiratory diagnosis, were newborns who 
never left the hospital, or had any of the following conditions: tracheostomy, cystic fibrosis, 
cancer with neutropenia, solid organ or hematopoietic stem cell transplant ≤90 days earlier, 
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active graft vs host disease or bronchiolitis obliterans, or HIV with CD4 cell count <200 
cells/mm3 (or CD4% <14%).
The methods for data collection, specimen collection, laboratory testing, and definitions for 
pathogen detection have been previously described.3 Data on underlying medical conditions, 
including neurologic disorders, were collected through a patient/caregiver interview and 
medical chart review. Blood and respiratory samples were collected from patients and tested 
for bacterial and viral pathogens by multiple modalities including bacterial culture, realtime 
polymerase chain reaction, and serology with methods as previously described.3
We identified 3 distinct groups for analysis: children with neurologic disorders, children 
with non-neurologic underlying conditions, and children with no underlying conditions. We 
categorized disorders as neurologic disorders based on literature review.16,22 In addition, we 
consulted with a behavior-development pediatrician (G.P.) to assist with categorizing 
neurologic disorders. Only those with possible neurologic sequelae attributable to the 
neurologic disorder as indicated from the literature were categorized as neurologic disorders. 
We defined neurologic disorders as a diagnosis of cerebral palsy, developmental delay, 
Down syndrome and non-Down syndrome chromosomal abnormalities, epilepsy, spinal cord 
abnormalities, and other neurologic disorders; if a child had a neurologic disorder and 
another non-neurologic underlying condition, he or she was categorized as having a 
neurologic disorder. Non-neurologic underlying conditions included asthma/reactive airway 
disease (RAD), other chronic lung disease, chronic kidney disease, chronic liver disease, 
congenital heart disease, diabetes mellitus, immunosuppressive conditions (either because of 
chronic conditions, medication use, HIV-infection with CD4 cell count >200 cells/mm3, and 
nondermatologic malignancies), and pre-term birth (in those aged <2 years old, defined as 
born at <37 weeks gestation). Those with no underlying conditions were defined as not 
having a neurologic disorder or a non-neurologic underlying condition.
Statistical Analyses
We describe the type and frequency of neurologic disorders occurring among children 
hospitalized with CAP and enrolled in the EPIC study. We compared epidemiologic and 
clinical characteristics, outcomes, and pathogens detected among children with neurologic 
disorders, non-neurologic underlying conditions, and no underlying conditions. Our primary 
outcome of clinical severity was intensive care unit (ICU) admission. We also examined 
other clinical outcomes including hospital length of stay (LOS), ICU LOS, invasive 
mechanical ventilation requirement and duration, receipt of vasopressors within 72 hours of 
ICU admission, and death. We performed bivariate and separate age-stratified analyses 
comparing the characteristics between children with neurologic disorders vs non-neurologic 
underlying conditions, and neurologic disorders vs no underlying conditions. In addition, we 
conducted subgroup analyses comparing the clinical outcomes of the subset of children with 
neurologic disorders and no other non-neurologic underlying conditions to the outcomes of 
children with non-neurologic underlying conditions and no underlying conditions; however, 
for our primary analysis, the neurologic disorders group includes children with a neurologic 
disorder who may also have non-neurologic disorders because there were few differences in 
the outcomes between these groups and because of sample size. We performed multivariable 
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logistic regression using stepwise elimination to further investigate clinical outcomes found 
to be more common among children with neurologic disorders; covariates for the regression 
models were based on significance on bivariate analysis and epidemiologic or biological 
plausibility.
Data were analyzed using SAS version 9.3 (SAS Institute, Cary, North Carolina). The χ2 or 
Fisher exact tests were used to compare proportions and the Wilcoxon rank sum test was 
used to evaluate distribution differences between continuous variables. All comparisons 
were 2-sided, and P values of <.05 was considered significant.
Results
Over the 2.5-year study period, 2638 (69.4%) of 3803 eligible children were enrolled; 
among which, 2358 (89.4%) children had radiographic CAP. Two hundred eighty (11.9%) of 
2358 children had a neurologic disorder, 934 (39.6%) had non-neurologic underlying 
conditions only, and 1144 (48.5%) had no underlying conditions. Among the 280 children 
with neurologic disorders, 146 (52.1%) had another non-neurologic underlying condition. 
Table I (available at www.jpeds.com) shows the types and frequencies of neurologic 
disorders among children hospitalized with CAP. Epilepsy was the most commonly reported 
neurologic disorder, occurring in 121 (43.2%) children; 82 (67.8%) of whom had another 
neurologic disorder in addition to epilepsy, the most common of which was cerebral palsy. 
Down syndrome was reported in 75 (26.8%) children with neurologic disorders.
Children with neurologic disorders were significantly older (median: 4.2 years, IQR: 1.7–9.8 
years) than those with non-neurologic underlying conditions (median: 2.7 years, IQR: 1.3–
6.2 years) and those with no underlying conditions (median: 1.8 years, IQR: 0.8–4.8 years). 
Children with neurologic disorders were significantly more likely than children with non-
neurologic underlying conditions to have congenital heart disease (30.4% vs 9.3%) and 
chronic lung disease (12.5% vs 6.3%) but were less likely to have asthma/RAD (29.6% vs 
74.5%) (Table II).
The presence of respiratory symptoms and fever on presentation was similar among all 
children, however, compared with children with non-neurologic underlying conditions and 
no underlying conditions, children with neurologic disorders were significantly more likely 
to have reported symptoms of seizures, as well as hypoxia and altered mental status 
documented on clinical examination (Table II). Of those with verified vaccination status, the 
proportion of children who received pneumococcal and Haemophilus influenzae type b 
vaccination was high in all 3 groups, ranging from 80.1%–86% (Table II); the proportion of 
children who received influenza vaccination was low in all 3 groups but significantly higher 
among children with neurologic disorders (41.7%) than those with non-neurologic 
underlying conditions (27.3%) or no underlying conditions (28.7%).
Children with neurologic disorders were significantly less likely to have a respiratory 
pathogen detected (69.4%) compared with children with non-neurologic underlying 
conditions (84.4%) and those with no underlying conditions (81.4%) (Table III). RSV was 
identified significantly less frequently in children with neurologic disorders (17.6%) 
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compared with both children with non-neurologic underlying conditions (27.8%) and no 
underlying conditions (30.7%). Adenovirus also was significantly less commonly detected 
among children with neurologic disorders (5.4%) vs those with non-neurologic underlying 
conditions (12.9%) and no underlying conditions (11.2%). In addition, rhinovirus was 
significantly less commonly detected among children with neurologic disorders (24.8%) 
compared with children with non-neurologic underlying conditions (35.5%) but was 
similarly detected among children with no underlying conditions (22.2%). The proportions 
of bacterial detections were similar among all 3 groups except for Streptococcus 
pneumoniae, which was similar among children with neurologic disorders (1.9%) and non-
neurologic underlying conditions (2.1%) but significantly more commonly detected in 
children with no underlying conditions (5.1%). In age-stratified analysis, the frequency of 
any pathogen detection decreased with increasing age in all comparison groups (Table IV; 
available at www.jpeds.com).
Children with neurologic disorders were significantly more likely to have longer hospital 
LOS compared with children with non-neurologic underlying conditions and no underlying 
conditions. Children with neurologic disorders were significantly more likely to be admitted 
to the ICU (36.4%) than those with non-neurologic underlying conditions (19.8%) and no 
underlying conditions (18.4%) (Table V). Table VI (available at www.jpeds.com) shows the 
characteristics of children hospitalized with CAP admitted to the ICU. The proportion of 
children requiring invasive mechanical ventilation was similar in all 3 groups (28.1%–
38.1%) as was the proportion of children with documented receipt of vasopressors within 72 
hours of ICU admissions (5.4%–9.5%). In age-stratified analysis, children with neurologic 
disorders still were significantly more likely to have hospital LOS >3 days and be admitted 
to the ICU compared with children with non-neurologic underlying conditions or no 
underlying conditions but the odds of those outcomes increased with older age (data not 
shown). Of the 3 deaths among children hospitalized with CAP; 1 was a child with a 
neurologic disorder and 2 were children with no underlying conditions. In a subgroup 
analysis of the clinical outcomes comparing a subset of children with neurologic disorders 
without other non-neurologic underlying conditions with children with non-neurologic 
underlying conditions and no underlying conditions, children with only neurologic disorders 
and no other underlying conditions still had longer hospital LOS and were more likely to 
require ICU admission, but there were no significant differences found in ICU LOS or 
requirements for or duration of invasive mechanical ventilation (Table VII; available at 
www.jpeds.com), similar to findings in the main analysis.
Because children with neurologic disorders (with and without other non-neurologic 
underlying conditions) were more likely to require ICU admission, we developed 
multivariable logistic regression models for the outcome of ICU admission which included 
the presence of a neurologic disorder; asthma/RAD; congenital heart disease; chronic lung 
disease; age group; race/ethnicity; report symptoms of seizures; presence of hypoxia; and 
tachypnea. Because age group was determined to be an effect modifier with neurologic 
disorders (P value <.01), we also created separate regression models stratified by age group; 
we excluded asthma/RAD from the <2-year-old age group because of the uncertainty of 
accurate diagnosis at that age. Using a stepwise elimination method, race/ethnicity and 
reports symptoms of seizures documented in the medical record fell out of the model and 
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were removed from all final models. In separate multivariable logistic regression models 
stratified by age group, which included the presence of a neurologic disorder, asthma/RAD 
(in the 2- to 4-year-old and 5- to 17-year-old age groups only), congenital heart disease, 
chronic lung disease, hypoxia, tachypnea, and the following interaction terms: neurologic 
disorder and congenital heart disease, congenital heart disease and hypoxia, asthma/RAD 
and hypoxia, asthma/RAD and tachypnea, neurologic disorder and chronic lung disease, 
asthma/RAD and chronic lung disease, hypoxia and chronic lung disease, tachypnea and 
chronic lung disease, and hypoxia and tachypnea; none of the interactions in the age-
stratified multivariate models was significant. In the final multivariate models, we found the 
presence of a neurologic disorder remained significantly associated with ICU admission 
among children ≥2 years but not among children <2 years (Table VIII).
Discussion
Children with neurologic disorders hospitalized with CAP were older and more likely to 
have congenital heart or lung disease than children without neurologic disorders. Children 
with neurologic disorders were more likely to have hospital LOS >3 days and require ICU 
admission than those without neurologic disorders but were similarly likely to require 
invasive mechanical ventilation or vasopressors within 72 hours of ICU admission. On 
multivariate age-stratified analysis controlling for congenital heart disease, asthma/RAD, 
tachypnea and hypoxia, having a neurologic disorder remained associated with ICU 
admission among children ≥2 years old. Overall, differences in pathogen detection in 
children with neurologic disorders were largely age-specific but a lower proportion of 
children with neurologic disorders had a respiratory pathogen detected compared with those 
without neurologic disorders.
In our study population of 2358 children hospitalized with CAP, 11.9% had a neurologic 
disorder. Children with neurologic disorders comprise a small proportion of the US pediatric 
population, but the heterogeneity of the disorders limit a single prevalence estimate. The 
estimated prevalence of epilepsy is 390 per 100 000 children and cerebral palsy is 240 per 
100 000 children.4 The estimated prevalence of birth defects range from a prevalence of 0.8–
3.5 per 100 000 live births for disorders such anencephaly, spina bifida, encephalocele, and 
chromosomal abnormalities except for Down syndrome, which is more common (14.5 per 
100 000 live births).6 Despite being uncommon in the general population, children with 
neurologic disorders have been reported to account for 5.3% of all pediatric 
hospitalizations.13 In a study using US claims data, investigators found that 11% of children 
hospitalized with respiratory infections had neurologic disorders.22 This is nearly identical 
to the proportion of children with neurologic disorders seen in our study.
Compared with children with non-neurologic underlying conditions and children with no 
underlying conditions, children with neurologic disorders in our study were older and more 
often had coexisting congenital heart disease (30.4%) and chronic lung disease (12.5%). 
This reflects the burden of chronic disease and medical complexity in this population.8–10
Overall, children with neurologic disorders were more likely to require ICU admission, our 
primary outcome of severe illness. However, on multivariate analysis the association 
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between neurologic disorder and ICU admission remained only for children ≥2 years of age. 
The reasons for this finding are not entirely clear and the EPIC dataset did not include 
reason for ICU admission. However, there are several possible reasons for this finding. First, 
it is possible that there was increased disability with increasing age or related to specific 
neurologic disorders, but we do not have detailed neurologic or functionality information in 
the EPIC dataset to assess this hypothesis. Second, it is possible that younger children with 
certain neurologic disorders, which were included in the case definition (such as epilepsy or 
developmental delay), may not have been fully diagnosed and, therefore, were not formally 
classified as having a neurologic disorder. Third, it is possible that children with neurologic 
disorders may have increasing disability with age because of their neurologic disorder alone 
(eg, impaired cough reflex) such that they were admitted to the ICU for aspiration risk and 
increased monitoring or treatment such as suctioning. Lastly, clinicians may have been more 
likely to admit all children younger than 2 years regardless of any underlying medical 
condition to the ICU for a respiratory admission for increased monitoring or treatment, thus, 
the effect of having a neurologic disorder would be decreased in this younger age group.
Although ICU admission has not previously been specifically evaluated among children 
hospitalized with CAP, the increased risk of ICU admission has previously been reported 
among children with neuromuscular disorders but hospitalized with specific viral infections. 
Wilkesmann et al20 reported that children with neuromuscular conditions hospitalized with 
RSV were more likely to require ICU admission than those without neuromuscular 
conditions (45% vs 10%). Chaves et al23 found that among children hospitalized with 
influenza, children with neuromuscular disorders were more likely to have ICU admissions 
or death compared with those without neuromuscular conditions (11% vs 3%). Previous 
studies have highlighted the disproportionate number of episodes of respiratory failure and 
deaths in children with neurologic disorders hospitalized with influenza or RSV 
infections.16,18,20,24,25 We found that children with neurologic disorders required invasive 
mechanical ventilation with the same frequency as children with non-neurologic underlying 
conditions and children with no underlying conditions. Because we comprehensively and 
prospectively evaluated children hospitalized with CAP directly, we did not identify cases 
through preferential testing or severity criteria which may have contributed to the differences 
between our study and the various previously published studies.
Overall, in each age group, respiratory pathogens were significantly less frequently detected 
in children with neurologic disorders compared with children with non-neurologic 
underlying conditions. Although the reasons for these differences are unclear and warrant 
further investigation, there are several possible explanations. More frequent aspiration 
without a discernible pathogen but still with clinical and radiographic pneumonia, may have 
contributed to the lower frequency of pathogen detection among children with neurologic 
disorders; the EPIC study did not systematically collect sputum or endotracheal aspirate 
specimens in the children to further assess this possibility.9,11,14,15 It is also possible that 
because pathogens were less frequently detected in older children overall,3 that the finding 
of fewer pathogens detected in children with neurologic disorders may be related to their 
older age compared with children with non-neurologic underlying conditions and no 
underlying conditions. Interestingly and specifically rhinovirus, adenovirus, and RSV were 
all less frequently detected in children with neurologic disorders compared with children 
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with non-neurologic medical conditions, of which asthma/RAD was most common; 
although we did not further stratify by underlying medical condition, these viruses have been 
associated with asthma and RAD in previous studies.26,27 Importantly, respiratory virus 
detections were more common than bacterial detections among children with neurologic 
disorders, as was also true for all other children hospitalized with CAP. In addition, the 
frequency of co-detections and specific pathogens detected were generally similar in all 3 
groups.
Per the Advisory Committee on Immunization Practices guidelines, all children >6 months 
of age and older should receive an annual influenza vaccination.28 Although our analysis 
demonstrated that children with neurologic disorders were more likely to have received 
influenza vaccination compared with children with no underlying condition (41.7% vs 
28.7%), this is well below the Healthy People 2020 target (70%) for annual pediatric 
influenza vaccination.29–31 This finding highlights that clinicians should strongly support 
influenza vaccination in these children. The Advisory Committee on Immunization Practices 
also recommends pneumococcal vaccination in children,32 coverage of which was high in 
our study, including among children with neurologic disorders.
These findings are subject to several limitations. First, data on the functional status of 
children enrolled in the EPIC study were not collected. Thus, we were unable to classify the 
degree of disability or ability to manage secretions caused by different neurologic disorders 
and the potential impact on outcomes. Similarly, we acknowledge that the neurologic 
disorders group is heterogeneous, but we used definitions that have been reported previously. 
In addition, in the assessment of specific disorders, although our numbers were small in any 
1 group, the clinical outcomes of the overall population of children with neurologic 
disorders and those of the subset of children with neurologic disorders and no other 
comorbidities were similar. Second, children with preexisting tracheostomy were excluded 
from this study, which may have excluded some of the children who are most severely 
neurologically compromised who have the highest risk for pneumonia. Third, aspiration can 
occur frequently in children with neurologic disorders,14,15,33 and it is possible that the 
lower proportion of pathogens detected in children with neurologic disorders was related to 
aspiration pneumonia when an etiologic agent was not detected. Sputum samples were not 
collected routinely in the children, and very few endotracheal aspirates were obtained in our 
study. Fourth, although we used a comprehensive array of diagnostic methods, detection of a 
pathogen does not necessarily denote causation.3 Fifth, we did not have data on the use of 
noninvasive positive pressure ventilation, thus, we are unable to describe all potential forms 
of respiratory support that may have been used during hospitalization. Sixth, the threshold 
and reasons for ICU admission vary among clinicians and institutions and, thus, have 
limitations as a marker for severity. Although we did not collect information on reason for 
ICU admission, we did find that most children admitted to the ICU had tachypnea, hypoxia, 
or altered mental status; however, there may be other factors, including clinician preferences 
or other nonclinical factors, for which we did not account. Finally, our study sites were 
tertiary care children’s hospitals, and the array of neurologic disorders and overall medical 
complexity in these patients may differ from those seen in nonreferral centers. This may 
have had a limited effect, however, because patients with more complex neurologic disorders 
would likely be referred to specialty centers regardless of the acute illness.13
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We demonstrated that children ≥2 years old with neurologic disorders were more likely to 
require ICU admission after controlling for asthma/RAD, congenital heart disease, hypoxia, 
and tachypnea. Overall, when stratified by age, the proportion of children with a detected 
pathogen was lower among children with neurologic disorders compared to children without 
neurologic disorders. Given the high proportion of and increased risk of severe illness 
among children with neurologic conditions hospitalized with CAP in our study, our findings 
underscore the vulnerable nature of children, the need for immunization in this population, 
and the requirement for comprehensive respiratory care in this vulnerable population.
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Table I
Neurologic disorders among children hospitalized with CAP (n = 280)
Neurologic disorders* No. (%)
Epilepsy 121 (43.2)
Down syndrome   75 (26.8)
Cerebral palsy   57 (20.4)
Developmental delay   43 (15.4)
Chromosomal abnormalities†   34 (12.1)
Spinal cord injury or abnormality 21 (7.5)
Other neurologic disorders*   75 (26.8)
 Hydrocephalus   10 (13.3)
 Hypotonia   7 (9.3)
 Muscular dystrophy   6 (8.0)
 Microcephaly   5 (6.7)
 Periventricular leukomalacia   5 (6.7)
 Metabolic disorders   4 (5.3)
 Agenesis of the corpus callosum   4 (5.3)
 Ischemic encephalopathy   4 (5.3)
 Spinal muscular atrophy type 1 and 2   4 (5.3)
 Neurofibromatosis   4 (5.3)
 Static encephalopathy   4 (5.3)
 Autism   3 (4.0)
 Smith-Magenis syndrome   3 (4.0)
 Spastic quadriplegia   3 (4.0)
 Intraventricular hemorrhage   2 (2.7)
 Holoprosencephaly   2 (2.7)
 Chiari malformation   2 (2.7)
 Fetal alcohol syndrome   1 (1.3)
 Ganglioglioma   1 (1.3)
 Langerhans cells histiocytosis CNS disease   1 (1.3)
 Myasthenia gravis   1 (1.3)
 Motor neuron disease   1 (1.3)
 Craniosynostosis   1 (1.3)
CNS, central nervous system.
*
Disorders are not mutually exclusive, and children may have more than 1 neurologic disorder.
†
Excluding Down syndrome.
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Table VIII
Age-stratified multivariate models of select clinical characteristics among children hospitalized with CAP with 
ICU admission as the outcome
Clinical characteristics
aOR (95%) CI
Age <2 y (n = 963) Age 2–4 y (n = 523) Age 5–17 y (n = 687)
Neurologic disorder 1.0 (0.5–1.8) 2.8 (1.4–5.5) 3.6 (2.2–5.9)
Asthma/RAD NA* 1.9 (1.2–3.0) 1.4 (0.9–2.1)
Congenital heart disease 1.5 (0.8–2.8) 0.9 (0.4–2.3) 1.0 (0.5–2.1)
Chronic lung disease 2.3 (1.1–4.7) 2.0 (0.8–4.6) 0.8 (0.3–2.6)
Hypoxia† 2.9 (2.2–4.0) 3.6 (2.2–5.8) 4.2 (2.7–6.4)
Tachypnea‡ 0.9 (0.7–1.3) 1.9 (1.1–3.1) 2.0 (1.2–3.2)
*Asthma/RAD excluded from the <2 year age group because of the uncertainty of accurate diagnosis at that age.
†
Hypoxia is defined as an oxygen saturation <92% on presentation or the receipt of any supplemental oxygen on presentation.
‡
Tachypnea is defined as ≥60 breaths per min in infants <2 mo; ≥50 breaths per min in infants ≥2 mo to <12 mo; ≥40 breaths per min in children 
≥1 y to <5 y; and ≥25 breaths per minute in ≥5 y to <18 y.
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